Design, fabrication and assembly of lab-on-a-chip and its uses

Pradeep, Aarathi; Raveendran, Jeethu; Babu, T G Satheesh

doi:10.1016/bs.pmbts.2021.07.021

Cited by 11 publications

(3 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the LOC chips are highly compact devices characterized by very small components, various microfabrication techniques have been applied for their development. On the basis of their operation principles, these techniques can be mainly classified as additive and subtractive techniques ( Figure 2 a) [ 35 ].…”

Section: Locs Design Available Technologies and Detection Methodsmentioning

confidence: 99%

Lab on a Chip Device for Diagnostic Evaluation and Management in Chronic Renal Disease: A Change Promoting Approach in the Patients’ Follow Up

et al. 2023

View full text Add to dashboard Cite

Lab-on-a-chip (LOC) systems are miniaturized devices aimed to perform one or several analyses, normally carried out in a laboratory setting, on a single chip. LOC systems have a wide application range, including diagnosis and clinical biochemistry. In a clinical setting, LOC systems can be associated with the Point-of-Care Testing (POCT) definition. POCT circumvents several steps in central laboratory testing, including specimen transportation and processing, resulting in a faster turnaround time. Provider access to rapid test results allows for prompt medical decision making, which can lead to improved patient outcomes, operational efficiencies, patient satisfaction, and even cost savings. These features are particularly attractive for healthcare settings dealing with complicated patients, such as those affected by chronic kidney disease (CKD). CKD is a pathological condition characterized by progressive and irreversible structural or functional kidney impairment lasting for more than three months. The disease displays an unavoidable tendency to progress to End Stage Renal Disease (ESRD), thus requiring renal replacement therapy, usually dialysis, and transplant. Cardiovascular disease (CVD) is the major cause of death in CKD, with a cardiovascular risk ten times higher in these patients than the rate observed in healthy subjects. The gradual decline of the kidney leads to the accumulation of uremic solutes, with negative effect on organs, especially on the cardiovascular system. The possibility to monitor CKD patients by using non-invasive and low-cost approaches could give advantages both to the patient outcome and sanitary costs. Despite their numerous advantages, POCT application in CKD management is not very common, even if a number of devices aimed at monitoring the CKD have been demonstrated worldwide at the lab scale by basic studies (low Technology Readiness Level, TRL). The reasons are related to both technological and clinical aspects. In this review, the main technologies for the design of LOCs are reported, as well as the available POCT devices for CKD monitoring, with a special focus on the most recent reliable applications in this field. Moreover, the current challenges in design and applications of LOCs in the clinical setting are briefly discussed.

show abstract

Section: Locs Design Available Technologies and Detection Methodsmentioning

confidence: 99%

Lab on a Chip Device for Diagnostic Evaluation and Management in Chronic Renal Disease: A Change Promoting Approach in the Patients’ Follow Up

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Benefits and Limitations Of Microfluidic Technologies In The...mentioning

confidence: 99%

“…48,49 Moreover, microdevices require specific development and manufacturing expertise, are not always commercially available and are often not simple to use in a more biological or clinical setting, limiting their current applications in these highly demanding environments. 50,51 Lastly, the throughput of multiple samples and large cohorts is often limited, as high throughput is often only achieved within one sample and automation and parallelization in terms of sample numbers are currently lacking. 52 Microdevices for the identification of animals and/or patients with suitable repertoires to screen As a first step in discovering new therapeutic antibody candidates, individuals or animals with suitable repertoires for screening need to be identified.…”

Section: Benefits and Limitations Of Microfluidic Technologies In The...mentioning

confidence: 99%